When should a peripheral blood smear be performed and how should its findings be interpreted and managed?

Peripheral Blood Smear Analysis: When to Perform and How to Interpret

Primary Recommendation

A peripheral blood smear should be performed and evaluated by a pathologist whenever there are abnormal CBC counts or leukocyte differentials, particularly when acute leukemia is suspected, and the findings must be interpreted in conjunction with complete clinical data, physical examination findings, and followed by appropriate ancillary testing including flow cytometry and cytogenetics when malignancy is identified. 1

When to Perform Peripheral Blood Smear

Strong Indications (Based on ASCO/CAP/ASH Guidelines)

For suspected acute leukemia, peripheral blood smear evaluation is a strong recommendation and should be performed alongside CBC review 1. The pathologist must evaluate the smear even before bone marrow examination, as it provides critical initial diagnostic information.

Additional Clinical Scenarios

Based on research evidence, peripheral blood smears provide added clinical value in specific situations:

• White blood cell abnormalities (25% yield clinically valuable findings) 2
• Red blood cell abnormalities (19% yield) 2
• Platelet disorders - particularly useful for distinguishing consumptive from underproduction thrombocytopenia and identifying inherited platelet disorders 3
• Screening for hematolymphoid neoplasms - especially chronic lymphocytic leukemia, hairy cell leukemia, or lymphocytic-variant hypereosinophilia 4

Important caveat: Only 23% of clinician-requested smears yield interpretations with potential added clinical value 2. Therefore, smears should be ordered judiciously based on specific CBC abnormalities rather than routinely.

How to Interpret Findings

Essential Pre-Analytical Requirements

Before interpreting the smear, the pathologist must have access to 1:

• Patient demographics: age, sex, ethnicity
• Hematologic history: prior disorders, predisposing conditions/syndromes
• Treatment history: cytotoxic therapy, immunotherapy, radiotherapy, growth factors, transfusions
• Physical examination findings: neurologic findings, tumor masses (mediastinal), cutaneous lesions, organomegaly
• Family history: hematologic disorders or malignancies

Systematic Approach to Smear Review

All respondents in a 2025 practice survey confirmed using CBC/differential and clinical history as essential components of smear review 5. The interpretation should follow this algorithmic approach 6:

1. Review automated CBC data first - identify specific abnormalities triggering the review
2. Assess smear quality - ensure adequate preparation
3. Sequential examination:
   • Low power: overall cellularity, distribution
   • High power: detailed morphology of RBCs, WBCs, platelets
4. Document specific morphologic abnormalities that could impact patient management and cannot be diagnosed by automated testing alone 2

Critical Morphologic Findings

For platelet disorders 3:

• Platelet size (small, normal, or large) helps classify inherited thrombocytopenias
• Platelet count and morphology distinguish consumptive from underproduction causes

For suspected malignancy 4:

• Small immunophenotypically abnormal lymphocyte populations may represent monoclonal B lymphocytosis or T-cell clonopathy of uncertain significance
• Integration with clinical context is essential before recommending flow cytometry

Management Based on Findings

When Acute Leukemia is Suspected or Confirmed

The following must be obtained 1:

1. Fresh bone marrow aspirate (strong recommendation) - unless contraindicated or adequate blasts present in peripheral blood
2. Conventional cytogenetic analysis (karyotype) - cannot be replaced by molecular/FISH testing
3. Flow cytometry - panel sufficient to distinguish AML (including APL), early T-ALL, B-ALL, and ambiguous lineage
4. Molecular genetic and/or FISH testing - in addition to, not instead of, karyotype

If bone marrow aspirate is inadequate: Peripheral blood may be used for diagnosis and ancillary studies if sufficient blasts are present 1.

For ALL Specifically

CSF sampling is a strong recommendation for patients receiving intrathecal therapy 1:

• Cell count must be performed
• Cytocentrifuge preparation for blast enumeration
• Pathologist review required

Reporting and Communication

Clinician-requested smears are more likely to be billed and issued as separate pathology reports 5. The report should:

• Clearly state morphologic abnormalities with potential clinical impact
• Distinguish findings that require additional workup
• Provide specific recommendations for ancillary testing when appropriate 4

Common Pitfalls to Avoid

1. Ordering smears without specific CBC abnormalities - leads to low yield (only 23% clinical value) 2
2. Interpreting smears without clinical context - can lead to overinterpretation of small abnormal populations of uncertain significance 4
3. Relying on peripheral blood alone when bone marrow is indicated - particularly in acute leukemia workup 1
4. Using molecular/FISH testing as replacement for conventional karyotype - all three are required 1
5. Failing to recognize confounding factors - recent growth factors, transfusions, or medications that obscure findings 1

Practical Considerations

Glass slide review remains the standard across most practices, though digital microscopy is emerging 5. All surveyed pathologists affirmed that peripheral blood smear review is an essential component of pathology training programs 5.

The turn-around time for traditional manual microscopy is approximately 3-4 hours 7, making it critical to order appropriately and provide complete clinical information upfront to avoid delays.